MedicalCV inks Premier valve pact
This article was originally published in The Gray Sheet
Three-year U.S. supply agreement with group purchasing firm Premier covers MedicalCV's Omnicarbon mechanical heart valve, approved by FDA in July 2001. The Minnesota firm currently holds less than 1% of the $400 mil. U.S. mechanical heart valve market - having generated $3.1 mil. in Omnicarbon sales during fiscal 2002. Concurrent with the Premier contract, MedicalCV expects to increase its U.S. direct sales force from three to nine, facilitating Omnicarbon sales and preparing for a third-quarter launch of the Northrup Universal annuloplasty system for mitral and tricuspid valve repair, pending FDA approval...
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.